InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (8 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
8
T+90 hit rate
67%
T+90 mean return
+6.6%
Across 6 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by KOZARICH JOHN W, Director. Insider active across 1 company, notably Ligand Pharmaceuticals INC. Aggregated, 19 filings have been published. Breakdown: 0 buy · 8 sells. Total volume traded: €347k. Activity tracked since 11 May 2021. The latest transaction was filed on 1 May 2026 (Cession). Regulator: SEC (Form 4). The full history is openly available.
Declarations19 total
80 shares@ US$227.36750.0004% mcap8.0% of flowCommon StockSEC:0002001011-26-000049
80 shares@ US$227.36750.0004% mcap8.0% of flowCommon StockSEC:0002001011-26-000049:0
1,252 shares0Common StockSEC:0002001011-24-000058:0
2,893 shares@ US$39.3514.7% of flowCommon StockSEC:0002001011-24-000048:0
1,142 shares0Common StockSEC:0000886163-23-000041:0
4,444 shares@ US$77.200943.5% of flowCommon StockSEC:0000899243-23-013275:0
6,408 shares@ US$18.8215.1% of flowCommon StockSEC:0000899243-23-012541:0
1,004 shares0Common StockSEC:0000886163-22-000080:0
7,335 shares@ US$12.530.0022% mcap42.4% of flowCommon StockSEC:0000886163-22-000033:0
630 shares0Common StockSEC:0000886163-21-000090:0
630 shares0Common StockSEC:0000886163-21-000090
4,835 shares@ US$10.1220.8% of flowCommon StockSEC:0000886163-21-000071
4,835 shares@ US$10.120.0011% mcap20.8% of flowCommon StockSEC:0000886163-21-000071:0
1,666 sharesCommon StockSEC:0000886163-16-000130:0
300 sharesCommon StockSEC:0000886163-16-000130:1
600 sharesCommon StockSEC:0000886163-16-000130:2
200 sharesCommon StockSEC:0000886163-16-000130:3
200 sharesCommon StockSEC:0000886163-16-000130:4
366 sharesCommon StockSEC:0000886163-16-000130:5
19 of 19 declarations
About KOZARICH JOHN W
John W. Kozarich is a Director at LIGAND PHARMACEUTICALS INC. In this role, he participates in overseeing operations and making strategic decisions. LIGAND PHARMACEUTICALS specializes in drug development. John contributes to guiding the growth and innovation strategies of the company.
